Last reviewed · How we verify
New TETA 4HCl Formulation
At a glance
| Generic name | New TETA 4HCl Formulation |
|---|---|
| Sponsor | Orphalan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. (PHASE3)
- Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride (PHASE2)
- Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- New TETA 4HCl Formulation CI brief — competitive landscape report
- New TETA 4HCl Formulation updates RSS · CI watch RSS
- Orphalan portfolio CI